MORGANTOWN – GATC Health Corp. announced on Wednesday that Dr. Rahul Gupta has joined the company as its new president.
California-based GATC Health is a tech-bio company leveraging artificial intelligence to transform drug discovery. Its GATC West Virginia subsidiary is headquartered in the WVU Innovation Corp. building.
Gupta served as director of the White House Office of National Drug Control Policy from 2021-2024. He was known in West Virginia as executive director of the Kanawha-Charleston Health Department from 2009-2014 and as state health officer from 2015-2108. He played a leading role in the state response to the 2014 Freedom Industries chemical spill that contaminated the water supply for about 300,000 people in the Kanawha River Valley.
GATC said, “Dr. Gupta’s distinguished career in public health leadership, medical innovation, and policy development, brings proven expertise to guide GATC into our next phase of strategic expansion.”
In his new role, GATC said, Gupta will collaborate with executive leadership and board of directors to refine and execute the company’s strategic vision. His responsibilities include fostering global partnerships, advancing regulatory education efforts, and championing GATC Health’s advanced AI technology on both national and international stages.
“His insights will drive commercialization strategies, investor relations, and market development as GATC continues to deliver impactful solutions in AI-driven drug discovery and development,” GATC said.
Jayson Uffens, chief technology officer at GATC Health, said, “Dr. Gupta’s proven expertise and forward-thinking leadership make him the ideal figure to join our team as we steer GATC Health into a new chapter. Our Multiomics Advanced Technology platform has already demonstrated the ability to dramatically reduce drug discovery timelines, lower costs, and mitigate risk. With Dr. Gupta’s expertise and experience, we are poised to accelerate the delivery of innovative therapies for critical health challenges.”
GATC said Gupta’s new role signifies a pivotal moment in the company’s evolution as it introduces new multiomics-based solutions for complex health challenges such as opioid use disorder, PTSD, diabetes, cancer, and more.
(GATC’s proprietary Multiomics Advanced Technology simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.)
GATC Health said it is also accelerating development through innovative investment partnerships. Gupta’s leadership will support GATC Health’s efforts to engage federal and state partners, including the FDA, NIH, and members of Congress, positioning the company as a leader in AI-enabled regulatory decision-making, advanced biotech collaboration, and innovation.
Gupta was born in India and raised in the United States. He is a board-certified internist with over 25 years of experience as a practicing physician, public health official, and global health advocate.
He has held academic appointments at Georgetown University School of Medicine and Harvard University and served as chief medical and health officer at the March of Dimes, where he oversaw global public health initiatives.
Gupta said, “I am excited to join GATC Health at this transformational time for the company and the biotech industry. The Multiomics Advanced Technology platform offers unparalleled potential to transform healthcare delivery and drug discovery. I look forward to collaborating with the talented team to accelerate breakthroughs that improve lives.”
